Amedica Corporation, a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, today announced that responses to the U.S. Food and Drug Administration inquiries regarding the Company’s cervical composite silicon nitride interbody device were submitted to the FDA on June 30, 2015.

Read More:
Amedica receives FDA feedback on proposed wear testing femoral head protocols

Scroll to Top